Default: Seminars in Cancer Biology

ISSN: 1044-579X

Journal Home

Journal Guideline

Seminars in Cancer Biology Q1 Unclaimed

Academic Press Inc. United States
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Seminars in Cancer Biology is a journal indexed in SJR in Cancer Research with an H index of 148. It has a price of 2840 €. It has an SJR impact factor of 3,908 and it has a best quartile of Q1. It is published in English.

Seminars in Cancer Biology focuses its scope in these topics and keywords: role, nuclear, cancer, natural, molecular, microrna, mechanismsthe, malignancy, lymphomagenesisa, inflammation, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

WOS Scopus
Categories: Cancer Research (Q1)

2840 €

Gold OA


Green OA

0 €

Non OA


Seminars in Cancer Biology


SJR Impact factor


H Index


Total Docs (Last Year)


Total Docs (3 years)


Total Refs


Total Cites (3 years)


Citable Docs (3 years)


Cites/Doc (2 years)



Aims and Scope

role, nuclear, cancer, natural, molecular, microrna, mechanismsthe, malignancy, lymphomagenesisa, inflammation, oncogenesis, products, receptorpositive, relationdisruption, researchnotch, resistance, stem, t, therapy, induced, impact, human, breast, cancerinfectious, cancermicroenvironmental, causal, cell, cells, cellular, cooperation, dietary, directions, ebv, estrogen, evolving, future,

Best articles

14-3-3 proteins and cancer biology

View more

A broad-spectrum integrative design for cancer prevention and therapy: The challenge ahead

View more

Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research

View more

AGEs, RAGEs and s-RAGE; friend or foe for cancer

View more

Alpha2beta1 integrin in cancer development and chemoresistance

View more

Apoptosis and cancer: where we are and where to go ...

View more

Assessing the anticancer effects associated with food products and/or nutraceuticals using in vitro and in vivo preclinical development-related pharmacological tests

View more

Augmenting the immunogenicity of carbohydrate tumor antigens

View more

Autocrine signaling in carcinoma: VEGF and the a6beta4 integrin

View more

Breast cancer stem cells: Features, key drivers and treatment options

View more

Burkitt lymphoma

View more

Cancer stem cells: Differentiation block or developmental back-tracking?

View more

Chemokines in neuroectodermal development and their potential implication in cancer stem cell-driven metastasis

View more

Chemokines in neuroectodermal tumour progression and metastasis

View more

Chromosomal translocation t(14;18) in healthy individuals

View more


View more

Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer

View more

Connecting mitotic instability and chromosome aberrations in cancer - can telomeres bridge the gap?

View more

Current criteria to establish human carcinogens

View more

Cyclin E as a prognostic and predictive marker in breast cancer

View more

Definition of tumor antigens suitable for vaccine construction

View more

Designer self-assembling peptide nanofiber scaffolds for 3D tissue cell cultures

View more

Epigenetic and proteolytic inactivation of 14-3-3s in breast and prostate cancers

View more

Epitope selection and development of peptide based vaccines to treat cancer

View more


No comments ... Be the first to comment!